Grace Therapeutics Files 8-K
Ticker: GRCE · Form: 8-K · Filed: Aug 27, 2025 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Grace Therapeutics, INC. (GRCE) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, pharmaceutical
TL;DR
Grace Therapeutics filed an 8-K, standard reporting, check for details.
AI Summary
Grace Therapeutics, Inc. filed an 8-K on August 27, 2025, reporting other events and financial statements. The company, formerly known as Acasti Pharma Inc., is incorporated in Delaware and headquartered in Princeton, New Jersey. This filing does not appear to contain specific financial transaction details or material events beyond routine reporting.
Why It Matters
This 8-K filing indicates Grace Therapeutics is fulfilling its regulatory reporting obligations. Investors should review the full filing for any disclosed material events or financial updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K without immediate disclosure of significant negative events, suggesting low immediate risk.
Key Numbers
- 001-35776 — SEC File Number (Identifies the company's SEC filings)
- 0001444192 — Central Index Key (Unique identifier for the filer)
Key Players & Entities
- Grace Therapeutics, Inc. (company) — Registrant
- Acasti Pharma Inc. (company) — Former Name
- August 27, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Princeton, New Jersey (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' reported; it only lists 'Other Events' as an item information category.
What is the significance of the former company name 'Acasti Pharma Inc.'?
Grace Therapeutics, Inc. was formerly known as Acasti Pharma Inc., with a name change date of August 28, 2008.
What is the primary business of Grace Therapeutics, Inc. according to the SIC code?
Grace Therapeutics, Inc. is classified under SIC code 2834, which corresponds to 'Pharmaceutical Preparations'.
When is Grace Therapeutics, Inc.'s fiscal year end?
The company's fiscal year ends on March 31st (0331).
What is the principal executive office address for Grace Therapeutics, Inc.?
The principal executive offices are located at 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540.
Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-08-27 08:08:12
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share GRCE The Nasdaq Stock Mar
Filing Documents
- ef20054617_8k.htm (8-K) — 30KB
- ef20054617_ex99-1.htm (EX-99.1) — 21KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-25-032847.txt ( ) — 189KB
- grce-20250827.xsd (EX-101.SCH) — 4KB
- grce-20250827_lab.xml (EX-101.LAB) — 21KB
- grce-20250827_pre.xml (EX-101.PRE) — 16KB
- ef20054617_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On August 27, 2025, Grace Therapeutics, Inc. (the "Company") issued a press release announcing that, on August 22, 2025, the U.S. Food and Drug Administration ("FDA") accepted the Company's New Drug Application ("NDA") for GTx-104 for formal review. GTx-104 is a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage patients. The FDA established a Prescription Drug User Fee Act (PDUFA) target date of April 23, 2026 for its review of the Company's NDA submission. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated August 27, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GRACE THERAPEUTICS, INC. Date: August 27, 2025 By: /s/ Prashant Kohli Prashant Kohli Chief Executive Officer